The recent studies published by Tan and Sharma’s group demonstrated that the bardoxolone analog, dh404, at low doses, attenuates atherosclerosis in diabetic Apolipoprotein E (ApoE) knockout mice (Tan et al., 2014) and protects against diabetes-induced endothelial dysfunction, both in vivo and in vitro (Sharma et al., 2017). This evidence concerns the gene APOE and endothelial dysfunction.